173 related articles for article (PubMed ID: 31839806)
1. SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis.
Goncalves J; Myung G; Park M; Jeong D; Ghil J
Therap Adv Gastroenterol; 2019; 12():1756284819891081. PubMed ID: 31839806
[TBL] [Abstract][Full Text] [Related]
2. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
Ben-Horin S; Yavzori M; Benhar I; Fudim E; Picard O; Ungar B; Lee S; Kim S; Eliakim R; Chowers Y
Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
[TBL] [Abstract][Full Text] [Related]
3. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G
PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.
Battat R; Lukin D; Scherl EJ; Pola S; Kumar A; Okada L; Yang L; Jain A; Siegel CA
Inflamm Bowel Dis; 2021 Aug; 27(9):1443-1451. PubMed ID: 33252119
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers.
Shin D; Lee Y; Kim H; Körnicke T; Fuhr R
J Clin Pharm Ther; 2017 Dec; 42(6):672-678. PubMed ID: 28675520
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
[TBL] [Abstract][Full Text] [Related]
7. Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay.
Rubin DT; Naik S; Kondragunta V; Rao T; Jain A
Curr Med Res Opin; 2017 May; 33(5):837-843. PubMed ID: 28145781
[TBL] [Abstract][Full Text] [Related]
8. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J
Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial.
Baert F; Kondragunta V; Lockton S; Vande Casteele N; Hauenstein S; Singh S; Karmiris K; Ferrante M; Gils A; Vermeire S
Gut; 2016 Jul; 65(7):1126-31. PubMed ID: 25862647
[TBL] [Abstract][Full Text] [Related]
10. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases.
Kay J; Cross RK; Feldman SR; Park Y; Hanauer SB
Adv Ther; 2024 Feb; 41(2):509-533. PubMed ID: 38110655
[TBL] [Abstract][Full Text] [Related]
11. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
Weinblatt ME; Baranauskaite A; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Baek I; Ghil J
Arthritis Rheumatol; 2018 Jun; 70(6):832-840. PubMed ID: 29439289
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry.
Tapete G; Bertani L; Pieraccini A; Lynch EN; Giannotta M; Morganti R; Biviano I; Naldini S; Mumolo MG; De Nigris F; Calella F; Bagnoli S; Minciotti M; Maltinti S; Rentini S; Ceccarelli L; Lionetti P; Milla M; Costa F
Inflamm Bowel Dis; 2022 Jan; 28(1):62-69. PubMed ID: 33570142
[TBL] [Abstract][Full Text] [Related]
13. SB5: An Adalimumab Biosimilar.
Frampton JE
BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
[TBL] [Abstract][Full Text] [Related]
15. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
[TBL] [Abstract][Full Text] [Related]
17. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.
Goncalves J; Santos M; Acurcio R; Iria I; Gouveia L; Matos Brito P; Catarina Cunha-Santos A; Barbas A; Galvão J; Barbosa I; Aires da Silva F; Alcobia A; Cavaco M; Cardoso M; Delgado Alves J; Carey JJ; Dörner T; Eurico Fonseca J; Palmela C; Torres J; Lima Vieira C; Trabuco D; Fiorino G; Strik A; Yavzori M; Rosa I; Correia L; Magro F; D'Haens G; Ben-Horin S; Lakatos PL; Danese S
Aliment Pharmacol Ther; 2018 Sep; 48(5):507-522. PubMed ID: 29873091
[TBL] [Abstract][Full Text] [Related]
18. Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi
Gisbert JP; Gaffney K; Young D; Ebbers HC; Girolomoni G
Expert Opin Biol Ther; 2022 Feb; 22(2):109-121. PubMed ID: 34918591
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature.
Park D; Yun J; Hwang SJ; Park SJ
Adv Ther; 2019 Feb; 36(2):442-450. PubMed ID: 30554330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]